NASDAQ:GDRX GoodRx (GDRX) Stock Price, News & Analysis $3.39 +0.01 (+0.30%) As of 09/21/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About GoodRx Stock (NASDAQ:GDRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get GoodRx alerts:Sign Up Key Stats Today's Range$3.38▼$3.4350-Day Range$2.87▼$3.8052-Week Range$1.77▼$5.81Volume557,159 shsAverage Volume1.13 million shsMarket Capitalization$1.16 billionP/E Ratio84.77Dividend YieldN/APrice Target$4.23Consensus RatingHold Company Overview GoodRx Holdings, Inc. (NASDAQ: GDRX) operates a consumer-focused healthcare technology platform in the United States. Its website and mobile application help consumers compare prescription drug prices at participating pharmacies and access coupons and other savings tools. GoodRx also provides information about medications, health conditions and treatment options. The company offers GoodRx Gold, a subscription-based program that provides additional prescription savings, as well as telehealth services that connect consumers with licensed healthcare professionals for certain medical consultations and prescriptions. Its platform also supports digital healthcare services and medication-related offerings from providers and pharmaceutical manufacturers. GoodRx was founded in 2011 and has developed its business around helping consumers navigate prescription costs and access healthcare services. The company serves consumers, healthcare providers, pharmacies and pharmaceutical manufacturers primarily within the United States.AI Generated. May Contain Errors. Read More GoodRx Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks83rd Percentile Overall ScoreGDRX MarketRank™: GoodRx scored higher than 83% of companies evaluated by MarketBeat, and ranked 75th out of 898 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingHold Consensus RatingGoodRx has received a consensus rating of Hold. The company's average rating score is 2.08, and is based on no strong buy ratings, 4 buy ratings, 6 hold ratings, and 3 sell ratings.Upside PotentialGoodRx has a consensus price target of $4.23, representing about 24.7% upside from its current price of $3.39.Amount of Analyst CoverageGoodRx has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about GoodRx's stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth25.00% Earnings GrowthEarnings for GoodRx are expected to grow by 25.00% in the coming year, from $0.16 to $0.20 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of GoodRx is 84.77, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 39.04.Price to Earnings Ratio vs. SectorThe P/E ratio of GoodRx is 84.77, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.80.Price to Earnings Growth RatioGoodRx has a PEG Ratio of 1.68. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioGoodRx has a P/B Ratio of 1.87. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about GoodRx's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.35% of the float of GoodRx has been sold short.Short Interest Ratio / Days to CoverGoodRx has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in GoodRx has recently decreased by 14.52%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGoodRx does not currently pay a dividend.Dividend GrowthGoodRx does not have a long track record of dividend growth. News and Social Media0.0 / 5News SentimentN/A Search InterestOnly 3 people have searched for GDRX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, GoodRx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,673,207.00 in company stock.Percentage Held by Insiders5.87% of the stock of GoodRx is held by insiders.Percentage Held by Institutions63.77% of the stock of GoodRx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about GoodRx's insider trading history. Receive GDRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GoodRx and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GDRX Stock News HeadlinesGoodRx Covers Whole Households and Pets in New Prescription PlanSeptember 4, 2026 | pymnts.comGoodRx offers health subscription for families, to launch as employee benefit in 2027September 3, 2026 | marketscreener.comMA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the country entirely - as concerns grow about the next phase of the AI market. One AI insider says investors should reassess their positions before September 30, pointing to a critical shift ahead for tech and AI-related stocks.September 22 at 1:00 AM | TradeSmith (Ad)GoodRx offers health subscription for families, to launch as employee benefit in 2027September 3, 2026 | reuters.comAnalysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ) and GoodRx Holdings (GDRX)August 28, 2026 | theglobeandmail.comInsider Selling: GoodRx (NASDAQ:GDRX) Major Shareholder Sells $437,819.12 in StockAugust 27, 2026 | insidertrades.comInsider Selling: GoodRx (NASDAQ:GDRX) Major Shareholder Sells $961,509.50 in StockAugust 22, 2026 | insidertrades.comReflecting on healthcare technology stocks’ Q2 earnings: GoodRx (NASDAQ:GDRX)August 13, 2026 | msn.comSee More Headlines GDRX Stock Analysis - Frequently Asked Questions How have GDRX shares performed this year? GoodRx's stock was trading at $2.71 at the beginning of 2026. Since then, GDRX stock has increased by 25.1% and is now trading at $3.39. How were GoodRx's earnings last quarter? GoodRx Holdings, Inc. (NASDAQ:GDRX) issued its quarterly earnings results on Wednesday, August, 5th. The company reported $0.08 EPS for the quarter, topping analysts' consensus estimates of $0.08 by $0.00. The firm's revenue was down 1.3% compared to the same quarter last year. Read the conference call transcript. When did GoodRx IPO? GoodRx (GDRX) raised $900 million in an IPO on Wednesday, September 23rd 2020. The company issued 34,615,384 shares at $24.00-$28.00 per share. Morgan Stanley, Goldman Sachs, J.P. Morgan and Barclays served as the underwriters for the IPO and BofA Securities, Citigroup, Credit Suisse, RBC Capital Markets, UBS Investment Bank, Cowen, Deutsche Bank Securities, Evercore ISI, Citizens Capital Markets, KKR, LionTree, Raymond James, SVB Leerink, Academy Securities, Loop Capital Markets, R. Seelaus and Ramirez were co-managers. Who are GoodRx's major shareholders? GoodRx's top institutional investors include Technology Crossover Management X Ltd. (0.48%), California State Teachers Retirement System (0.17%), Bank of New York Mellon Corp (0.05%) and VIRGINIA RETIREMENT SYSTEMS ET Al (0.05%). Insiders that own company stock include Scott Wagner, Francisco Partners Iv, LP and Equity Vii LP Spectrum. View institutional ownership trends. How do I buy shares of GoodRx? Shares of GDRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of GoodRx own? Based on aggregate information from My MarketBeat watchlists, some other companies that GoodRx investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), AUO (AUOTY) and DiamondRock Hospitality (DRH). Company Calendar Last Earnings8/05/2026Today9/21/2026Next Earnings (Estimated)11/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 GDRX's financial health is in the Green zone, according to TradeSmith. GDRX has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Technology Sub-IndustryHealthcare Technology Current SymbolNASDAQ:GDRX CIK1809519 Webwww.goodrx.com Phone855-268-2822FaxN/AEmployees697Year Founded2011Price Target and Rating Average Price Target for GoodRx$4.23 High Price Target$5.00 Low Price Target$2.75 Potential Upside/Downside+24.7%Consensus RatingHold Rating Score (0-4)2.08 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)$0.04 Trailing P/E Ratio84.77 Forward P/E Ratio21.19 P/E Growth1.68Net Income$30.44 million Net Margins2.07% Pretax Margin5.27% Return on Equity7.22% Return on Assets2.53% Debt Debt-to-Equity Ratio0.74 Current Ratio1.38 Quick Ratio1.38 Sales & Book Value Annual Sales$796.85 million Price / Sales1.46 Cash Flow$0.40 per share Price / Cash Flow8.45 Book Value$1.81 per share Price / Book1.87Miscellaneous Outstanding Shares342,570,000Free Float322,465,000Market Cap$1.16 billion OptionableOptionable Beta1.59 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:GDRX) was last updated on 9/22/2026 by MarketBeat.com Staff. From Our Partners10% yields… from a gold security?Most stocks yield under 2%. Even gold stocks average less than 1%. One gold security, backed by one of the wor...Golden Portfolio | Sponsored$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...American Alternative | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredThe next convergence is hereIn 2006, a flooded mine at Cigar Lake sent uranium prices from the 50 range to 136 in eight months. This pa...Digest Publishing | SponsoredThis AI Stock Reminds One Analyst of Early NvidiaJeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GoodRx Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GoodRx With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
